{"related:1q9w2O4QEhoJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5":[{"title":"Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer","url":"https://air.unimi.it/handle/2434/349662","authors":["F Di Nicolantonio","F Di Nicolantonio M Martini","F Di Nicolantonio M Martini F Molinari…"],"year":2008,"numCitations":1893,"pdf":"https://air.unimi.it/bitstream/2434/349662/2/2008%20Di%20Nicolantonio%20et%20al%20JCO.pdf","citationUrl":"http://scholar.google.com/scholar?cites=1878582612586442710&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:1q9w2O4QEhoJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=1878582612586442710&hl=en&as_sdt=0,5","publication":"air.unimi.it","p":1,"exp":1596898397351},{"title":"BRAF wild-type is required for response to panitumumab or cetuximab in metastatic colorectal cancer","url":"https://www.researchgate.net/profile/Federica_Di_Nicolantonio/publication/23465803_Wild-Type_BRAF_Is_Required_for_Response_to_Panitumumab_or_Cetuximab_in_Metastatic_Colorectal_Cancer/links/09e4150bd0e1d081f3000000.pdf","authors":["F Di Nicolantonio","F Di Nicolantonio M Martini","F Di Nicolantonio M Martini F Molinari…"],"year":0,"numCitations":1,"pdf":"https://www.researchgate.net/profile/Federica_Di_Nicolantonio/publication/23465803_Wild-Type_BRAF_Is_Required_for_Response_to_Panitumumab_or_Cetuximab_in_Metastatic_Colorectal_Cancer/links/09e4150bd0e1d081f3000000.pdf","citationUrl":"http://scholar.google.com/scholar?cites=3631386139300269462&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:lg1FK3RGZTIJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=3631386139300269462&hl=en&as_sdt=0,5","publication":"researchgate.net"},{"title":"Une forme sauvage de BRAF est nécessaire à la réponse au panitumumab ou au cétuximab dans le cancer colorectal métastatique","url":"http://www.academia.edu/download/36506577/5705.pdf","authors":["F Di Nicolantonio","F Di Nicolantonio M Martini","F Di Nicolantonio M Martini F Molinari…"],"year":2008,"numCitations":0,"pdf":"http://www.academia.edu/download/36506577/5705.pdf","relatedUrl":"http://scholar.google.com/scholar?q=related:HySmYFTBz9IJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=15190572636286886943&hl=en&as_sdt=0,5","publication":"academia.edu"},{"title":"PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies","url":"https://cancerres.aacrjournals.org/content/69/5/1851.short","authors":["A Sartore"],"year":2009,"numCitations":812,"pdf":"https://cancerres.aacrjournals.org/content/canres/69/5/1851.full.pdf","citationUrl":"http://scholar.google.com/scholar?cites=12909333262434760504&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:OPeOojQqJ7MJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=12909333262434760504&hl=en&as_sdt=0,5","publication":"AACR"},{"title":"Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a …","url":"https://www.sciencedirect.com/science/article/pii/S1470204510701303","authors":["W De Roock","W De Roock B Claes","W De Roock B Claes D Bernasconi","W De Roock B Claes D Bernasconi J De Schutter…"],"year":2010,"numCitations":2014,"pdf":"https://portal.findresearcher.sdu.dk/en/publications/effects-of-kras-braf-nras-and-pik3ca-mutations-on-the-efficacy-of","citationUrl":"http://scholar.google.com/scholar?cites=12619741451722051524&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:xE8q8_xTIq8J:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=12619741451722051524&hl=en&as_sdt=0,5","publication":"Elsevier"},{"title":"Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer","url":"https://air.unimi.it/handle/2434/349676","authors":["RG Amado","RG Amado M Wolf","RG Amado M Wolf M Peeters","RG Amado M Wolf M Peeters E Van Cutsem","RG Amado M Wolf M Peeters E Van Cutsem S Siena…"],"year":2008,"numCitations":3478,"pdf":"https://air.unimi.it/bitstream/2434/349676/2/2008%20Amado%20et%20al%20J%20Clin%20Oncol.pdf","citationUrl":"http://scholar.google.com/scholar?cites=10363341736328015575&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:167P32b80Y8J:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=10363341736328015575&hl=en&as_sdt=0,5","publication":"air.unimi.it"},{"title":"Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer","url":"https://www.researchgate.net/profile/Michel_Ducreux/publication/38062629_Analysis_of_PTEN_BRAF_and_EGFR_status_in_determining_benefit_from_cetuximab_therapy_in_wild-type_KRAS_metastatic_colon_cancer/links/56742d0008aebcdda0de1f25.pdf","authors":["P Laurent"],"year":2009,"numCitations":760,"pdf":"https://www.researchgate.net/profile/Michel_Ducreux/publication/38062629_Analysis_of_PTEN_BRAF_and_EGFR_status_in_determining_benefit_from_cetuximab_therapy_in_wild-type_KRAS_metastatic_colon_cancer/links/56742d0008aebcdda0de1f25.pdf","citationUrl":"http://scholar.google.com/scholar?cites=7479556983156263354&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:uklSonK5zGcJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=7479556983156263354&hl=en&as_sdt=0,5","publication":"researchgate.net"},{"title":"K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer","url":"https://www.nejm.org/doi/full/10.1056/nejmoa0804385","authors":["CS Karapetis","CS Karapetis S Khambata"],"year":2008,"numCitations":3753,"pdf":"https://www.nejm.org/doi/full/10.1056/nejmoa0804385","citationUrl":"http://scholar.google.com/scholar?cites=7042567775535507856&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:kCloJxQ6vGEJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=7042567775535507856&hl=en&as_sdt=0,5","publication":"Mass Medical Soc"},{"title":"KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer","url":"https://www.nature.com/articles/6605177","authors":["F Loupakis","F Loupakis A Ruzzo","F Loupakis A Ruzzo C Cremolini","F Loupakis A Ruzzo C Cremolini B Vincenzi…"],"year":2009,"numCitations":582,"pdf":"https://www.nature.com/articles/6605177","citationUrl":"http://scholar.google.com/scholar?cites=6025879252329927582&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:npOF5kA5oFMJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=6025879252329927582&hl=en&as_sdt=0,5","publication":"nature.com"},{"title":"Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti–epidermal growth factor receptor antibody …","url":"https://cancerres.aacrjournals.org/content/67/6/2643.short","authors":["S Benvenuti","S Benvenuti A Sartore"],"year":2007,"numCitations":937,"pdf":"https://cancerres.aacrjournals.org/content/canres/67/6/2643.full.pdf","citationUrl":"http://scholar.google.com/scholar?cites=9391470921892478007&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:N7zPmQs1VYIJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=9391470921892478007&hl=en&as_sdt=0,5","publication":"AACR"}]}